Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
August 24, 2023 09:00 ET
|
Tarsus Pharmaceuticals, Inc
Demodex blepharitis impacts approximately 25 million eye care patients in the U.S. – or 1 out of every 12 adults. XDEMVY is indicated for all adult patients with Demodex blepharitis and is available...
Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease
December 15, 2022 08:30 ET
|
Tarsus Pharmaceuticals, Inc
Positive Phase 1b Callisto data shows that TP-05 is well tolerated and safety data supports progression to Phase 2a Phase 2a Carpo trial to evaluate the safety, tolerability, and proof-of-activity of...
Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting
October 25, 2022 08:30 ET
|
Tarsus Pharmaceuticals, Inc
Saturn-2 follow-up data to be presented on TP-03 for the treatment of Demodex blepharitis Tarsus recently submitted NDA to the FDA for TP-03 Data from an investigator-initiated trial evaluating...
Tarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Data Evaluating TP-03 for the Treatment of Demodex Blepharitis at Upcoming Eye Care Meetings
September 27, 2022 12:00 ET
|
Tarsus Pharmaceuticals, Inc
Positive data to be presented at WCC VIII and AAO 2022 conferences in Chicago Tarsus recently submitted NDA to the FDA for TP-03 IRVINE, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Tarsus...
Tarsus Pharmaceuticals, Inc. Presents Data from Two Pioneering Studies on the Prevalence and Impact of Demodex Blepharitis at the American Academy of Optometry 2021 Annual Meeting
November 04, 2021 09:45 ET
|
Tarsus Pharmaceuticals, Inc
Titan real-world prevalence study data reveals that Demodex blepharitis accounts for over two-thirds of all blepharitis cases and is highly prevalent in many commonly seen patient groups New Titan...
Tarsus Pharmaceuticals, Inc. Appoints Pharmaceutical and Healthcare Industry Leader Rosemary A. Crane to Board of Directors
August 12, 2021 09:00 ET
|
Tarsus Pharmaceuticals, Inc
Ms. Crane brings over 30 years of experience in executive leadership, commercialization, and business development in the pharmaceutical and healthcare industries IRVINE, Calif., Aug. 12, 2021 ...
Tarsus Pharmaceuticals, Inc. Reports Second Quarter 2021 Financial Results and Provides Business and Clinical Updates
August 04, 2021 17:30 ET
|
Tarsus Pharmaceuticals, Inc
Announced positive results of the Saturn-1 pivotal trial evaluating TP-03 for the treatment of Demodex blepharitis; results presented at the 2021 American Society of Cataract and Refractive Surgery...
Tarsus Pharmaceuticals, Inc. Presents New Saturn-1 Pivotal Trial Data and Titan Real-World Prevalence Study Results at ASCRS 2021
July 24, 2021 18:00 ET
|
Tarsus Pharmaceuticals, Inc
New Saturn-1 data demonstrated a strong patient responder rate with 95% of Demodex blepharitis patients treated with TP-03 achieving ≤0.5 mites per lash and 93% improving by at least one collarette...
Tarsus Pharmaceuticals, Inc. to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare Conference
July 07, 2021 16:05 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply...
Tarsus Pharmaceuticals, Inc. Announces Positive Results of Saturn-1 Pivotal Trial Evaluating TP-03 for the Treatment of Demodex Blepharitis
June 21, 2021 06:00 ET
|
Tarsus Pharmaceuticals, Inc
Saturn-1 Phase 2b/3 trial met all primary and secondary endpoints, and demonstrated significant, clinically meaningful outcomes with no serious treatment-related adverse events and no...